Saturday 17 October 2026 Export MNOV’s income statement to Excel — free account

MediciNova, Inc.

MediciNova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $409,700.00, down 59.0% from fiscal 2023. In the quarter to June 2026, revenue grew 240.6%, EPS grew 28.6% and free cash flow grew 16.8%, each against the same quarter a year earlier.

1.42 0.03 −2.07%

Follow MNOV

Alert me

Market cap: $71.4M
P/E: 0.0×
Fwd P/E: −5.0×
Dividend yield: —
F-score: n/a
Altman Z: −4.10
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.73

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	1	—

Insider Ownership 5.12%

Capital & Financial Ratios $m

Market Cap 71.38

Revenue 0.92

Net Income (10.75)

Free Cash Flow (9.12)

Net Debt (25.42)

Current Ratio 8.75

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (5.04)

P/S ratio 75.94

P/B ratio 1.88

Past 5Y EPS Growth —

This Y EPS Growth (6.25%)

Next Y EPS Growth (75.16%)

Next Y revenue growth 78.18%

Next 5Y EPS Growth 27.01%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 92.68%

10-year low 10-year high

P/B against its own 10 years 42.06%

10-year low 10-year high

EV/Sales against its own 10 years 92.68%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	51	40	31	25
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	51	41	31	26

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	2
	3	3	4	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	7.61%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	2.42%	(10.23%)	(16.03%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	—	0	0	0	0
’23	—	—	1	—	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(4)	(2)	(2)	(2)	(10)
’24	(4)	(3)	(2)	(2)	(11)
’23	(3)	(2)	(1)	0	(7)
’22	(4)	(2)	(3)	(4)	(13)
’21	(4)	1	(3)	(4)	(9)
’20	(3)	(2)	(4)	(2)	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(4)	(2)	(2)	(2)	(10)
’24	(4)	(3)	(2)	(2)	(11)
’23	(3)	(2)	(1)	0	(7)
’22	(4)	(2)	(3)	16	7
’21	(4)	1	(3)	(4)	(9)
’20	(3)	(2)	(4)	(2)	(11)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.05)	(0.05)	—	—	—
’25	(0.06)	(0.07)	(0.06)	(0.05)	(0.24)
’24	(0.06)	(0.05)	(0.06)	(0.06)	(0.23)
’23	(0.06)	(0.06)	(0.01)	(0.04)	(0.17)
’22	(0.07)	(0.08)	(0.07)	(0.06)	(0.29)
’21	0.00	(0.09)	(0.07)	(0.04)	(0.21)
’20	(0.06)	(0.10)	(0.08)	(0.07)	(0.31)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	3.50	4.40	6.49	6.36	2.79	2.57	1.95	1.38	1.12	1.13	Analyst estimates 2026–2028 Powerpack
	High	10.16	7.85	14.50	13.37	13.25	10.81	3.18	2.66	2.55	2.20
People
People	Employees	10	9	9	8	—	11	13	13	13	6
	Revenue/emp, $m	0.00	0.00	0.00	0.00	—	0.37	0.00	0.08	0.00	0.07
Income, $m
Income, $m	Revenue	—	—	—	—	—	4	—	1	—	0
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	100.00	0.00	100.00	—	7.59
	EBT	(11)	(13)	(15)	(13)	(14)	(10)	(14)	(9)	(11)	(12)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(250.94)	0.00	(856.85)	0.00	(2,927.02)
	Net income	(11)	(11)	(15)	(13)	(14)	(10)	(14)	(9)	(11)	(12)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.08	0.00	0.02	0.00	0.01
	Earnings	(0.33)	(0.32)	(0.36)	(0.30)	(0.31)	(0.21)	(0.29)	(0.17)	(0.23)	(0.24)
	Cash flow	(0.20)	(0.20)	(0.22)	(0.21)	(0.24)	(0.19)	(0.26)	(0.15)	(0.22)	(0.20)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	0.41	0.00	0.00	0.00
	Free cash flow	(0.20)	(0.20)	(0.22)	(0.21)	(0.24)	(0.19)	0.14	(0.15)	(0.22)	(0.20)
	Book value	1.05	1.10	1.78	1.74	1.61	1.72	1.43	1.27	1.07	0.85
	Shares, m	33	35	41	43	44	49	49	49	49	49
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	—	0.00	—	0.00
	P/S	—	—	—	—	—	12.97	—	7.33	—	45.60
	P/B	—	—	—	—	—	1.56	—	1.30	—	1.55
	EV/Sales	—	—	—	—	—	5.86	—	2.71	—	23.74
	EV/FCF	—	—	—	—	—	(6.23)	—	2.41	—	(3.41)
Cash, $m
Cash, $m	Operating cash flow	(7)	(7)	(9)	(9)	(11)	(9)	(13)	(7)	(11)	(10)
	Capex	0	—	0	0	0	0	20	0	0	0
	Free cash flow	(7)	(7)	(9)	(9)	(11)	(9)	7	(7)	(11)	(10)
Balance, $m
Balance, $m	Working capital	23	25	61	62	59	69	56	48	38	27
	Total debt	—	—	—	0	0	1	1	—	—	—
	Net debt	(24)	(28)	(62)	(64)	(60)	(71)	(58)	(51)	(40)	(31)
	Shareholders’ equity	35	39	73	75	71	84	70	62	53	42
Returns, %
Returns, %	ROA	(27.96)	(26.82)	(24.33)	(16.55)	(17.92)	(12.45)	(17.42)	(12.21)	(18.09)	(23.65)
	ROIC	(65.31)	(76.45)	(90.25)	(78.99)	(78.49)	(52.14)	(77.78)	(54.38)	(65.23)	(77.01)
	ROE	(32.30)	(30.51)	(26.26)	(17.49)	(18.95)	(13.08)	(18.28)	(12.93)	(19.24)	(25.50)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NTRB Nutriband Inc.	$76.2M	— (loss-making)	4.6×	−29.72% (below 0%: shrinking)	n/m	+55.46% (above 0%: growing)	41.58%	(203.57%)	Compare
CRDF Cardiff Oncology, Inc.	$75.5M	— (loss-making)	— (loss-making)	−14.05% (below 0%: shrinking)	n/m	−41.36% (below 0%: shrinking)	100.00%	(9,245.19%)	Compare
ACRV Acrivon Therapeutics, Inc.	$75.4M	— (loss-making)	—	—	n/m	+12.59% (above 0%: growing)	0.00%	0.00%	Compare
OKYO OKYO Pharma Limited Sponsored ADR	$75.1M	— (loss-making)	—	—	n/m	+37.39% (above 0%: growing)	0.00%	—	Compare
PDSB PDS Biotechnology Corporation	$72.8M	— (loss-making)	—	—	n/m	+69.32% (above 0%: growing)	0.00%	0.00%	Compare
HRTX Heron Therapeutics, Inc.	$71.5M	— (loss-making)	— (loss-making)	+1.25% (above 0%: growing)	n/m	+78.75% (above 0%: growing)	69.28%	(5.43%)	Compare
MNOV MediciNova, Inc.	$71.4M	— (loss-making)	— (loss-making)	+240.56% (above 0%: growing)	n/m	+16.75% (above 0%: growing)	69.33%	(554.36%)
CGTX Cognition Therapeutics, Inc.	$69.7M	— (loss-making)	—	—	n/m	+45.35% (above 0%: growing)	0.00%	0.00%	Compare
MAIA MAIA Biotechnology, Inc.	$69.2M	— (loss-making)	—	—	n/m	−63.23% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$73.9M	—	—	−14.05%	—	+41.37%	0.00%	0.00%

All 614 Biotechnology stocks →

MediciNova, Inc. (MNOV) key facts

Concern: MediciNova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $409,700.00, down 59.0% from fiscal 2023.
MediciNova, Inc. (MNOV) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MNOV traded at $1.42, a market capitalization of $71.4 million.
Return on equity was −25.5% and debt-to-equity 0.00.
Its Altman Z-score is −4.10 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.